Form 4: Amgen Director Tyler Jacks Reports Acquisition of 719 Shares of Common Stock
SEC Form 4 Filing
Director Tyler Jacks reports the acquisition of 719 shares of Amgen common stock on May 31, 2024, through the vesting of restricted stock units.
Summary
- On May 31, 2024, Tyler Jacks, a director of Amgen Inc., acquired 719 shares of Amgen's common stock.
- The acquisition was a result of the vesting of restricted stock units (RSUs) granted under the Amgen Inc. 2009 Director Incentive Program.
- The RSUs vested immediately and are payable in shares of Amgen's common stock on a one-to-one basis.
- The reported transaction increased Jacks' direct ownership to 16,005 shares, which includes 2,170 Dividend Equivalents (DEs).
- The DEs are credited on the director's vested but deferred RSUs and are paid out in shares of the Company's Common Stock on a one-to-one basis along with a cash payment for any remaining fractional share amount.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by a director, which is neither particularly positive nor negative.
Positives
- The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Directors often receive stock-based compensation, and their transactions are closely monitored by investors for insights into their confidence in the company's prospects.
Comparison to Industry Standards
- Director stock ownership is a common practice in publicly traded companies like Amgen, and is comparable to companies such as Johnson & Johnson, Pfizer, and Merck.
- The Amgen Inc. 2009 Director Incentive Program is similar to equity compensation plans offered by other large pharmaceutical companies to align director interests with shareholder value.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders.
- It provides transparency regarding director stock ownership, which can influence investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/31/2024 | Date of transaction: Acquisition of Amgen common stock. |
| 06/01/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.